GALECTIN THERAPEUTICS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
GALECTIN THERAPEUTICS INC. (GALT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.84% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-14
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-06-30 was 3.84%, a 14.29% decline year-over-year.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.84%, a 14.29% decline year-over-year.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-06-30 was 4.48%.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.48%, a 11.44% increase year-over-year.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.48%, a 15.17% increase from fiscal 2024.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.89%, a 1.30% increase from fiscal 2023.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.84%, a 107.57% increase from fiscal 2022.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.85%, a 180.30% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 144 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 147 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 150 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 153 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 156 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 159 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 162 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 3.84% 10-Q · filed 2026-08-14 | |||||||||||
| 2026-03-31 | 3.84% 10-Q · filed 2026-05-15 | |||||||||||
| 2025-12-31 | 4.48% 10-K · filed 2026-03-31 | |||||||||||
| 2025-09-30 | 4.48% 10-Q · filed 2025-11-14 | |||||||||||
| 2025-06-30 | 4.48% 10-Q · filed 2026-08-14 | 4.48% 10-Q · filed 2025-08-14 | ||||||||||
| 2025-03-31 | 4.48% 10-Q · filed 2026-05-15 | |||||||||||
| 2024-12-31 | 3.89% 10-K · filed 2026-03-31 | |||||||||||
| 2024-09-30 | 3.88% 10-Q · filed 2025-11-14 | |||||||||||
| 2024-06-30 | 3.88% 10-Q · filed 2025-08-14 | |||||||||||
| 2024-03-31 | 4.02% 10-Q · filed 2025-05-15 | |||||||||||
| 2023-12-31 | 3.84% 10-K · filed 2025-03-31 | |||||||||||
| 2023-09-30 | 3.84% 10-Q · filed 2024-11-14 | |||||||||||
| 2023-06-30 | 3.76% 10-Q · filed 2024-08-13 | |||||||||||
| 2023-03-31 | 3.76% 10-Q · filed 2024-05-15 | |||||||||||
| 2022-12-31 | 1.85% 10-K · filed 2024-03-29 | |||||||||||
| 2022-09-30 | 1.56% 10-Q · filed 2023-11-13 | |||||||||||
| 2022-06-30 | 1.56% 10-Q · filed 2023-08-14 | |||||||||||
| 2022-03-31 | 1.23% 10-Q · filed 2023-05-15 | |||||||||||
| 2021-12-31 | 0.66% 10-K · filed 2023-03-30 | |||||||||||
| 2021-09-30 | 0.58% 10-Q · filed 2022-11-14 | |||||||||||
| 2021-06-30 | 0.57% 10-Q · filed 2022-08-15 | |||||||||||
| 2021-03-31 | 0.54% 10-Q · filed 2022-05-16 | |||||||||||
| 2020-12-31 | 1.26% 10-K · filed 2022-03-31 | |||||||||||
| 2020-09-30 | 1.26% 10-Q · filed 2021-11-15 | |||||||||||
| 2020-06-30 | 1.55% 10-Q · filed 2021-08-16 | |||||||||||
| 2020-03-31 | 1.55% 10-Q · filed 2021-05-17 | |||||||||||
| 2019-12-31 | 2.68% 10-K · filed 2021-03-31 | |||||||||||
| 2019-09-30 | 2.68% 10-Q · filed 2020-11-09 | |||||||||||
| 2019-06-30 | 2.68% 10-Q · filed 2020-08-10 | |||||||||||
| 2019-03-31 | 2.68% 10-Q · filed 2020-05-11 | |||||||||||
| 2018-12-31 | 2.47% 10-K · filed 2020-03-16 | |||||||||||
| 2018-09-30 | 2.47% 10-Q · filed 2019-11-12 | |||||||||||
| 2018-06-30 | 2.47% 10-Q · filed 2019-08-09 | |||||||||||
| 2018-03-31 | 2.18% 10-Q · filed 2019-05-10 | |||||||||||
| 2017-12-31 | 2.05% 10-K · filed 2019-03-06 | |||||||||||
| 2017-06-30 | 0.00% 10-Q · filed 2017-08-14 | |||||||||||
| 2017-03-31 | 0.00% 10-Q · filed 2017-05-15 | |||||||||||
| 2016-12-31 | 1.49% 10-K · filed 2018-03-29 | |||||||||||
| 2016-09-30 | 1.70% 10-Q · filed 2017-11-07 | |||||||||||
| 2016-06-30 | 1.70% 10-Q · filed 2017-08-14 | |||||||||||
| 2016-03-31 | 1.70% 10-Q · filed 2017-05-15 | |||||||||||
| 2015-12-31 | 1.65% 10-K · filed 2017-03-28 | |||||||||||
| 2015-09-30 | 1.65% 10-Q · filed 2015-11-09 | |||||||||||
| 2015-06-30 | 1.58% 10-Q · filed 2016-11-08 | 1.64% 10-Q · filed 2015-08-10 | ||||||||||
| 2015-03-31 | 1.64% 10-Q · filed 2016-05-10 | |||||||||||
| 2014-12-31 | 1.58% 10-K · filed 2016-03-15 | |||||||||||
| 2014-09-30 | 1.58% 10-Q · filed 2015-11-09 | |||||||||||
| 2014-06-30 | 1.58% 10-Q · filed 2015-08-10 | |||||||||||
| 2014-03-31 | 1.58% 10-Q · filed 2015-05-11 | |||||||||||
| 2013-12-31 | 1.17% 10-K · filed 2016-03-15 | 1.68% 10-K · filed 2014-03-21 | ||||||||||
| 2013-09-30 | 1.17% 10-Q · filed 2014-11-10 | 1.75% 10-Q · filed 2013-11-12 | ||||||||||
| 2013-06-30 | 0.97% 10-Q · filed 2014-08-07 | 1.75% 10-Q · filed 2013-08-14 | ||||||||||
| 2013-03-31 | 0.80% 10-Q · filed 2014-05-13 | 1.76% 10-Q · filed 2013-05-10 | ||||||||||
| 2012-12-31 | 0.90% 10-K · filed 2015-03-18 | 1.84% 10-K · filed 2013-03-29 | ||||||||||
| 2012-09-30 | 0.84% 10-Q · filed 2012-11-09 | 1.87% 10-Q · filed 2012-11-09 | ||||||||||
| 2012-06-30 | 0.91% 10-Q · filed 2012-08-10 | 1.98% 10-Q · filed 2012-08-10 | ||||||||||
| 2011-12-31 | 1.90% 10-K · filed 2013-03-29 | |||||||||||
| 2011-09-30 | 1.91% 10-Q · filed 2012-11-09 | |||||||||||
| 2011-06-30 | 1.91% 10-Q · filed 2012-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |